Pharmacodynamic optimization of β-lactams in the patient care setting

di Nicolau, David P
Pubblicazione 2008

Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models

di Abdelraouf, Kamilia, Nicolau, David P.
Pubblicato in Antimicrob Agents Chemother (2016)

1312. Metallo-β-lactamase-Producing Enterobacterales (MBL-EB): Is it Time to Rethink Our Assessment Tools?

di Abdelraouf, Kamilia, Nicolau, David P
Pubblicato in Open Forum Infect Dis (2020)

In Vivo Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase- Producing Klebsiella pneumoniae

di Bulik, Catharine C., Nicolau, David P.
Pubblicazione 2010

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

di Bulik, Catharine C., Nicolau, David P.
Pubblicazione 2011

Reply to “Double-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive Klebsiella pneumoniae”

di Bulik, Catharine C., Nicolau, David P.
Pubblicazione 2012

Tigecycline Displays In Vivo Bactericidal Activity against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae after 72-Hour Exposure Period

di Tessier, Pamela R., Nicolau, David P.
Pubblicazione 2013

Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers

di Crandon, Jared L., Nicolau, David P.
Pubblicazione 2013

In Vitro Activity of Novel Gyrase Inhibitors against a Highly Resistant Population of Pseudomonas aeruginosa

di Tessier, Pamela R., Nicolau, David P.
Pubblicazione 2013

To Add or Not To Add Polysorbate 80: Impact on Colistin MICs for Clinical Strains of Enterobacteriaceae and Pseudomonas aeruginosa and Quality Controls

di Sutherland, Christina A., Nicolau, David P.
Pubblicazione 2014

Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection

di Thabit, Abrar K, Nicolau, David P
Pubblicato in Infect Dis (Auckl) (2015)

In Vivo Activities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae

di Crandon, Jared L., Nicolau, David P.
Pubblicato in Antimicrob Agents Chemother (2015)

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae

di Crandon, Jared L., Nicolau, David P.
Pubblicato in Pathogens (2015)

Stability of Ertapenem 100 mg/mL at Room Temperature

di Kuti, Joseph L, Nicolau, David P
Pubblicato in Can J Hosp Pharm (2016)

An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

di Thabit, Abrar K, Nicolau, David P
Pubblicato in Infect Drug Resist (2016)

Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy

di Sutherland, Christina A., Nicolau, David P.
Pubblicato in J Thorac Dis (2017)

Cefazolin potency against methicillin-resistant Staphylococcus aureus: a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections

di Nicolau, David P, Silberg, Barry N
Pubblicato in Infect Drug Resist (2017)

Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complic...

di Monogue, Marguerite L., Nicolau, David P.
Pubblicato in Antimicrob Agents Chemother (2017)

Clostridium difficile infection in the elderly: an update on management

di Asempa, Tomefa E, Nicolau, David P
Pubblicato in Clin Interv Aging (2017)

Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology

di Lasko, Maxwell J., Nicolau, David P.
Pubblicato in Curr Infect Dis Rep (2020)